Cardiovascular Risk Factors and Morbidity in Long-Term Survivors of Testicular Cancer: A 20-Year Follow-Up Study

Myocardial infarction and other major vascular events during chemotherapy for testicular cancer

(2010) K.- P. Dieckmann et al.   ANNALS OF ONCOLOGY

Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79

(2010) R. Haring et al.   EUROPEAN HEART JOURNAL

Coronary Vasospasm and Atrial Fibrillation Associated with Ondansetron Therapy

(2009) Pamela L Havrilla et al.   ANNALS OF PHARMACOTHERAPY

Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer

(2009) R Altena et al.   BRITISH JOURNAL OF CANCER

The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease

(2009) A. M. Traish et al.   JOURNAL OF ANDROLOGY

Inflammation in Atherosclerosis

(2009) Peter Libby et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer Survivors

(2009) M. Brydoy et al.   JNCI-Journal of the National Cancer Institute

Cardiovascular risk in long-term survivors of testicular cancer

(2008) David J. Vaughn et al.   CANCER

Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-κB dependent pathway

(2008) Minghua Yu et al.   CANCER SCIENCE

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

(2008) Susanne Krege et al.   EUROPEAN UROLOGY

Predicted cardiovascular mortality and reported cardiovascular morbidity in testicular cancer survivors

(2008) H. S. Haugnes et al.   Journal of Cancer Survivorship